| NSABP B-59 | A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Aztezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo | 1 | 3 | Breast | 1,520 | 1,550 | 06/01/2021 |
| NSABP FB-12 | An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant ACT+Trastuzumab and Pertuzumab in Early Stage HER-2 Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER-2 Signaling Transduction | 0 | 2 | Breast | 54 | 17 | 09/14/2021 |
| NSABP FB-14 | A Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer | 3 | 2 | Breast | 29 | 5 | 07/02/2021 |
| NSABP FC-10 | A Phase IB Study of Pembolizumab in Combination with Pemetrexed and Oxaliplatin in Subjects with Chemo-refractory Metastatic Colorectal Cancer | 1 | 1-B | Colorectal | 33 | 35 | 07/02/2021 |
| NSABP FC-11 | A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated | 1 | 2 | Colorectal | 35 | 25 | 07/02/2021 |
| NSABP B-54-I | Phase III Study Evaluating Palbociclib (PD-0332991) and a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (PENELOPE) Global Accrual = 1250 | 2 | 3 | Breast | 171 | 171 | 02/02/2021 |
| NSABP B-56-I | A Randomized, Placebo-Controlled, Double Blind Phase 3 Study Evaluating the Safety and Efficacy of the Addition of Velaparib Plus Carboplatin versus the Addition of Carobplatin to Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (Abbvie) Global Accrual = 634 | 3 | 3 | Breast | 16 | 16 | 01/20/2021 |
| NSABP B-57-I | PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer (PALLAS) Global Accrual = 5793 | 2 | 3 | Breast | 439 | 439 | 01/15/2021 |
| NSABP B-58 | A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | 2 | 3 | Breast | 150 | 190 | 11/20/2020 |
| NSABP B-50-I | A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2 Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (KATHERINE) Global Accrual = 1487 | 2 | 3 | Breast | 366 | 361 | 07/23/2020 |
| NSABP FB-10 Phase 1B | A Phase 1B/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DMI) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer | 3 | 1-B | Breast | 41 | 28 | 07/06/2021 |
| NSABP FB-10 Phase II | A Phase 1B/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DMI) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer | 3 | 2 | Breast | 22 | 22 | 07/06/2021 |
| NSABP FB-13 | An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive, HER2-Negative Primary Breast Cancer | 3 | 2 | Breast | 76 | 24 | 07/06/2021 |
| NSABP FR-2 | A Phase II Study to Assess the Activity of PD-L 1 Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer | 3 | 2 | Colorectal | 41 | 45 | 07/06/2021 |
| NSABP B-60 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy | 0 | 3 | Breast | 275 | 91 | 08/20/2021 |
| NSABP B-61 lidERA | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC-9545 Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen-Receptor Positive , HER2 Negative Early Breast Cancer | 0 | 3 | Breast | 350 | 125 | 06/23/2023 |
| NSABP C-14 | CORRECT- MRD II: Second COloRectal cancer clinical validation study to predict REcurrence using a Circulating Tumor DNA assay to detect Minimal Residual Disease. | 0 | OBS | Colorectal | 750 | 501 | |
| NSABP FC-12 | A Single Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy | 3 | 2 | Colorectal | 31 | 0 | |
| NSABP B-62 CAMBRIA-1 | A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence | 0 | 3 | Breast | 430 | 22 | 02/02/2023 |
